Elevated pretreatment squamous cell Carcinoma Antigen indicates unfavorable treatment outcomes in cervical cancer patients receiving definitive radiotherapy

Objective To investigate the prognostic value of pretreatment squamous cell carcinoma antigen (SCC Ag) levels for treatment failure prediction in patients with cervical cancer. Methods A quantity 985 satisfying eligibility criteria were included, a median follow-up duration 63.7 months. The optimal cutoff SCC Ag was verified by receiver operating characteristic (ROC) curve. Five-year disease-free survival (DFS), overall (OS), and local control (LC) rates evaluated utilizing Kaplan-Meier method. Log-rank test Cox proportional hazards model implemented to recognize independent predictors. Results 8.85 ng/mL. Patients ≥ ng/mL presented significantly inferior 5-year DFS (63.8% vs. 81.8%), OS (71.7% 88.7%), LC (80.5% 91.0%) compared those < (all p 0.001). results multivariate analysis indicated that level an predictor (HR,1.772; 95% CI, 1.366 2.299; Conclusion Pretreatment is effective factor cancer undergoing definitive radiotherapy, ROC-identified elevated indicates unfavorable outcomes.